panobinostat + epoetin alfa

This is a **combination drug** consisting of panobinostat, a non-selective histone deacetylase (HDAC) inhibitor, and epoetin alfa, a recombinant erythropoietin analogue. - **Panobinostat** acts as a pan-HDAC inhibitor across class I, II, and IV HDACs resulting in increased acetylation of histones and non-histone proteins, leading to cell cycle arrest and apoptosis of tumor cells. It also inhibits the aggresome pathway relevant for protein degradation, and has approved use in combination therapy for refractory multiple myeloma[1][2][3][4][5][6]. - **Epoetin alfa** is a recombinant human erythropoietin protein used primarily to stimulate red blood cell production for the treatment of anemia, including that associated with chemotherapy, chronic kidney disease, or HIV therapy[7].

Other names

panobinostat(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-AbseamedBinocritBiopoin